Phospho-AKT1 (Thr308) Polyclonal Antibody

Background:
The serine-threonine protein kinase AKT1 is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery.

Research Area: Cancer, Epigenetics and Nuclear Signaling, Metabolism, Signal Transduction

Synonyms:
AKT 1, AKT, AKT1, AKT1, MGC99656, PKB, PKB-ALPHA, PRKBA, Protein Kinase B Alpha, Protein kinase B, Proto-oncogene c-Akt, RAC Alpha, RAC, RAC-alpha serine/threonine-protein kinase, RAC-PK-alpha

Immunogen: Synthesized peptide derived from human Akt around the phosphorylation site of Thr308

Swissprot: P31749

Calculated MW: 56 kDa
Observed MW: 56-60 kDa

Purification Method: Affinity purification

Buffer: PBS with 0.02% sodium azide, 0.5% BSA and 50% glycerol, pH7.4

Concentration: 1 mg/mL
Dilution: WB 1:500-1:2000, ELISA 1:40000

Storage:
Store at -20°C. Avoid freeze / thaw cycles.

Alternative for product with catalog number:
sc-7126,sc-1619,sc-1618,sc-55523,sc-8312

Citation(s):
https://pubmed.ncbi.nlm.nih.gov/29559323/